




A




B




C




D



E



F



S2 Fig. Kaplan-Meier curves showing (A) Comparison of progression-free survival (PFS) between patients aged ≥ 75 years versus aged < 75 years. (B) Comparison of overall survival (OS) between patients aged ≥ 75 years versus aged < 75 years. (C) Comparison of PFS between patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 versus 2. (D) Comparison of OS between patients with ECOG PS 0-1 versus 2. (E) Comparison of PFS between patients who experienced immune-related adverse effects (AEs) versus who did not (F) Comparison of OS between patients who experienced immune-related AEs versus who did not.